nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—metabolic syndrome X	0.651	1	CbGaD
Lenalidomide—CDH5—artery—metabolic syndrome X	0.0229	0.213	CbGeAlD
Lenalidomide—CDH5—endothelium—metabolic syndrome X	0.0194	0.18	CbGeAlD
Lenalidomide—CDH5—blood vessel—metabolic syndrome X	0.0179	0.166	CbGeAlD
Lenalidomide—CDH5—cardiovascular system—metabolic syndrome X	0.00797	0.0739	CbGeAlD
Lenalidomide—CDH5—adipose tissue—metabolic syndrome X	0.00703	0.0652	CbGeAlD
Lenalidomide—Gastrointestinal tract irritation—Metformin—metabolic syndrome X	0.00575	0.0492	CcSEcCtD
Lenalidomide—CDH5—liver—metabolic syndrome X	0.00493	0.0457	CbGeAlD
Lenalidomide—CRBN—adipose tissue—metabolic syndrome X	0.00447	0.0414	CbGeAlD
Lenalidomide—Pomalidomide—TNF—metabolic syndrome X	0.00415	0.412	CrCbGaD
Lenalidomide—Sinus congestion—Metformin—metabolic syndrome X	0.00413	0.0353	CcSEcCtD
Lenalidomide—PTGS2—artery—metabolic syndrome X	0.00397	0.0368	CbGeAlD
Lenalidomide—Azotaemia—Metformin—metabolic syndrome X	0.00385	0.033	CcSEcCtD
Lenalidomide—Loose stools—Metformin—metabolic syndrome X	0.00371	0.0317	CcSEcCtD
Lenalidomide—Toothache—Metformin—metabolic syndrome X	0.00338	0.0289	CcSEcCtD
Lenalidomide—PTGS2—endothelium—metabolic syndrome X	0.00335	0.0311	CbGeAlD
Lenalidomide—Respiratory distress—Metformin—metabolic syndrome X	0.00323	0.0277	CcSEcCtD
Lenalidomide—Upset stomach—Metformin—metabolic syndrome X	0.00313	0.0268	CcSEcCtD
Lenalidomide—CRBN—liver—metabolic syndrome X	0.00313	0.029	CbGeAlD
Lenalidomide—PTGS2—blood vessel—metabolic syndrome X	0.00309	0.0287	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—IGF1—metabolic syndrome X	0.00302	0.0264	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—TRIB3—metabolic syndrome X	0.00302	0.0264	CbGpPWpGaD
Lenalidomide—Thalidomide—TNF—metabolic syndrome X	0.00267	0.266	CrCbGaD
Lenalidomide—Fungal infection—Metformin—metabolic syndrome X	0.00266	0.0228	CcSEcCtD
Lenalidomide—Rhinorrhoea—Metformin—metabolic syndrome X	0.00253	0.0217	CcSEcCtD
Lenalidomide—Rigors—Metformin—metabolic syndrome X	0.00251	0.0215	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CYBA—metabolic syndrome X	0.00248	0.0217	CbGpPWpGaD
Lenalidomide—PTGS2—Nicotinate metabolism—NAMPT—metabolic syndrome X	0.00239	0.0209	CbGpPWpGaD
Lenalidomide—Contusion—Metformin—metabolic syndrome X	0.00235	0.0201	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—CYBA—metabolic syndrome X	0.00234	0.0205	CbGpPWpGaD
Lenalidomide—Pomalidomide—PTGS2—metabolic syndrome X	0.00197	0.196	CrCbGaD
Lenalidomide—Neuropathy—Metformin—metabolic syndrome X	0.00193	0.0165	CcSEcCtD
Lenalidomide—ABCB1—blood vessel—metabolic syndrome X	0.00191	0.0177	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—metabolic syndrome X	0.00181	0.0158	CbGpPWpGaD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I3—metabolic syndrome X	0.00176	0.0154	CbGpPWpGaD
Lenalidomide—Ear pain—Metformin—metabolic syndrome X	0.00175	0.015	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—FGF21—metabolic syndrome X	0.00166	0.0145	CbGpPWpGaD
Lenalidomide—Nasal congestion—Metformin—metabolic syndrome X	0.00164	0.014	CcSEcCtD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—metabolic syndrome X	0.00161	0.0141	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—HSD11B1—metabolic syndrome X	0.00158	0.0138	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—metabolic syndrome X	0.00157	0.0137	CbGpPWpGaD
Lenalidomide—PTGS2—Eicosanoid Synthesis—PLA2G6—metabolic syndrome X	0.00155	0.0136	CbGpPWpGaD
Lenalidomide—Hypoglycaemia—Metformin—metabolic syndrome X	0.00153	0.0131	CcSEcCtD
Lenalidomide—Lethargy—Metformin—metabolic syndrome X	0.00152	0.013	CcSEcCtD
Lenalidomide—Pain in extremity—Metformin—metabolic syndrome X	0.00149	0.0128	CcSEcCtD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT1—metabolic syndrome X	0.00147	0.0128	CbGpPWpGaD
Lenalidomide—Migraine—Metformin—metabolic syndrome X	0.00147	0.0126	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—metabolic syndrome X	0.00139	0.0121	CbGpPWpGaD
Lenalidomide—Dehydration—Metformin—metabolic syndrome X	0.00139	0.0119	CcSEcCtD
Lenalidomide—PTGS2—Arachidonic acid metabolism—EPHX2—metabolic syndrome X	0.00138	0.0121	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H3—metabolic syndrome X	0.00138	0.0121	CbGpPWpGaD
Lenalidomide—PTGS2—cardiovascular system—metabolic syndrome X	0.00138	0.0128	CbGeAlD
Lenalidomide—Liver function test abnormal—Metformin—metabolic syndrome X	0.00138	0.0118	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—metabolic syndrome X	0.00136	0.0119	CbGpPWpGaD
Lenalidomide—Abdominal pain upper—Metformin—metabolic syndrome X	0.00136	0.0117	CcSEcCtD
Lenalidomide—PTGS2—kidney—metabolic syndrome X	0.00135	0.0125	CbGeAlD
Lenalidomide—Breast disorder—Metformin—metabolic syndrome X	0.00135	0.0115	CcSEcCtD
Lenalidomide—Cramp muscle—Metformin—metabolic syndrome X	0.00134	0.0115	CcSEcCtD
Lenalidomide—Nasopharyngitis—Metformin—metabolic syndrome X	0.00133	0.0114	CcSEcCtD
Lenalidomide—Abdominal distension—Metformin—metabolic syndrome X	0.0013	0.0111	CcSEcCtD
Lenalidomide—Influenza—Metformin—metabolic syndrome X	0.00129	0.011	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—AKT1—metabolic syndrome X	0.00128	0.0112	CbGpPWpGaD
Lenalidomide—Thalidomide—PTGS2—metabolic syndrome X	0.00127	0.126	CrCbGaD
Lenalidomide—Pancreatitis—Metformin—metabolic syndrome X	0.00126	0.0108	CcSEcCtD
Lenalidomide—Sweating increased—Metformin—metabolic syndrome X	0.00125	0.0107	CcSEcCtD
Lenalidomide—Angina pectoris—Metformin—metabolic syndrome X	0.00125	0.0107	CcSEcCtD
Lenalidomide—Abdominal discomfort—Metformin—metabolic syndrome X	0.00123	0.0106	CcSEcCtD
Lenalidomide—PTGS2—adipose tissue—metabolic syndrome X	0.00122	0.0113	CbGeAlD
Lenalidomide—Neutropenia—Metformin—metabolic syndrome X	0.0012	0.0103	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.0012	0.0102	CcSEcCtD
Lenalidomide—Infestation—Metformin—metabolic syndrome X	0.00115	0.00983	CcSEcCtD
Lenalidomide—Infestation NOS—Metformin—metabolic syndrome X	0.00115	0.00983	CcSEcCtD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT1—metabolic syndrome X	0.00113	0.00987	CbGpPWpGaD
Lenalidomide—Neuropathy peripheral—Metformin—metabolic syndrome X	0.00113	0.00964	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NOS3—metabolic syndrome X	0.00109	0.00956	CbGpPWpGaD
Lenalidomide—Hepatobiliary disease—Metformin—metabolic syndrome X	0.00109	0.0093	CcSEcCtD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—NR1I3—metabolic syndrome X	0.00106	0.00928	CbGpPWpGaD
Lenalidomide—Bradycardia—Metformin—metabolic syndrome X	0.00105	0.00899	CcSEcCtD
Lenalidomide—Rhinitis—Metformin—metabolic syndrome X	0.00103	0.00885	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—NOS3—metabolic syndrome X	0.00103	0.00902	CbGpPWpGaD
Lenalidomide—Hepatitis—Metformin—metabolic syndrome X	0.00103	0.00883	CcSEcCtD
Lenalidomide—Hypoaesthesia—Metformin—metabolic syndrome X	0.00103	0.00878	CcSEcCtD
Lenalidomide—Oedema peripheral—Metformin—metabolic syndrome X	0.00102	0.00869	CcSEcCtD
Lenalidomide—Connective tissue disorder—Metformin—metabolic syndrome X	0.00101	0.00867	CcSEcCtD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—metabolic syndrome X	0.00101	0.00884	CbGpPWpGaD
Lenalidomide—Eye disorder—Metformin—metabolic syndrome X	0.000964	0.00825	CcSEcCtD
Lenalidomide—PTGS2—Eicosanoid Synthesis—GGT1—metabolic syndrome X	0.000958	0.00838	CbGpPWpGaD
Lenalidomide—Cardiac disorder—Metformin—metabolic syndrome X	0.000957	0.00819	CcSEcCtD
Lenalidomide—Flushing—Metformin—metabolic syndrome X	0.000957	0.00819	CcSEcCtD
Lenalidomide—Angiopathy—Metformin—metabolic syndrome X	0.000936	0.00801	CcSEcCtD
Lenalidomide—Immune system disorder—Metformin—metabolic syndrome X	0.000931	0.00797	CcSEcCtD
Lenalidomide—Mediastinal disorder—Metformin—metabolic syndrome X	0.000929	0.00795	CcSEcCtD
Lenalidomide—Chills—Metformin—metabolic syndrome X	0.000925	0.00792	CcSEcCtD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—metabolic syndrome X	0.000924	0.00808	CbGpPWpGaD
Lenalidomide—Erythema—Metformin—metabolic syndrome X	0.000898	0.00768	CcSEcCtD
Lenalidomide—Malnutrition—Metformin—metabolic syndrome X	0.000898	0.00768	CcSEcCtD
Lenalidomide—Flatulence—Metformin—metabolic syndrome X	0.000884	0.00757	CcSEcCtD
Lenalidomide—Dysgeusia—Metformin—metabolic syndrome X	0.000879	0.00752	CcSEcCtD
Lenalidomide—Muscle spasms—Metformin—metabolic syndrome X	0.000863	0.00739	CcSEcCtD
Lenalidomide—ABCB1—cardiovascular system—metabolic syndrome X	0.000853	0.00791	CbGeAlD
Lenalidomide—PTGS2—liver—metabolic syndrome X	0.000853	0.00791	CbGeAlD
Lenalidomide—Vision blurred—Metformin—metabolic syndrome X	0.000846	0.00724	CcSEcCtD
Lenalidomide—Tremor—Metformin—metabolic syndrome X	0.000841	0.0072	CcSEcCtD
Lenalidomide—ABCB1—kidney—metabolic syndrome X	0.000835	0.00774	CbGeAlD
Lenalidomide—Ill-defined disorder—Metformin—metabolic syndrome X	0.000833	0.00713	CcSEcCtD
Lenalidomide—Malaise—Metformin—metabolic syndrome X	0.000809	0.00693	CcSEcCtD
Lenalidomide—Syncope—Metformin—metabolic syndrome X	0.000805	0.00689	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—metabolic syndrome X	0.000801	0.00701	CbGpPWpGaD
Lenalidomide—Palpitations—Metformin—metabolic syndrome X	0.000793	0.00679	CcSEcCtD
Lenalidomide—Loss of consciousness—Metformin—metabolic syndrome X	0.000789	0.00675	CcSEcCtD
Lenalidomide—Hypertension—Metformin—metabolic syndrome X	0.000775	0.00663	CcSEcCtD
Lenalidomide—Chest pain—Metformin—metabolic syndrome X	0.000764	0.00654	CcSEcCtD
Lenalidomide—Myalgia—Metformin—metabolic syndrome X	0.000764	0.00654	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.000759	0.0065	CcSEcCtD
Lenalidomide—Discomfort—Metformin—metabolic syndrome X	0.000755	0.00646	CcSEcCtD
Lenalidomide—ABCB1—adipose tissue—metabolic syndrome X	0.000752	0.00698	CbGeAlD
Lenalidomide—Oedema—Metformin—metabolic syndrome X	0.000733	0.00627	CcSEcCtD
Lenalidomide—Infection—Metformin—metabolic syndrome X	0.000728	0.00623	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—metabolic syndrome X	0.000722	0.00632	CbGpPWpGaD
Lenalidomide—Shock—Metformin—metabolic syndrome X	0.000721	0.00617	CcSEcCtD
Lenalidomide—Nervous system disorder—Metformin—metabolic syndrome X	0.000718	0.00615	CcSEcCtD
Lenalidomide—Thrombocytopenia—Metformin—metabolic syndrome X	0.000717	0.00614	CcSEcCtD
Lenalidomide—Skin disorder—Metformin—metabolic syndrome X	0.000712	0.00609	CcSEcCtD
Lenalidomide—Hyperhidrosis—Metformin—metabolic syndrome X	0.000708	0.00606	CcSEcCtD
Lenalidomide—Anorexia—Metformin—metabolic syndrome X	0.000698	0.00598	CcSEcCtD
Lenalidomide—Hypotension—Metformin—metabolic syndrome X	0.000685	0.00586	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000667	0.00571	CcSEcCtD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—metabolic syndrome X	0.000661	0.00579	CbGpPWpGaD
Lenalidomide—Paraesthesia—Metformin—metabolic syndrome X	0.000658	0.00563	CcSEcCtD
Lenalidomide—Dyspnoea—Metformin—metabolic syndrome X	0.000653	0.00559	CcSEcCtD
Lenalidomide—Somnolence—Metformin—metabolic syndrome X	0.000651	0.00557	CcSEcCtD
Lenalidomide—Dyspepsia—Metformin—metabolic syndrome X	0.000645	0.00552	CcSEcCtD
Lenalidomide—Decreased appetite—Metformin—metabolic syndrome X	0.000637	0.00545	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000632	0.00541	CcSEcCtD
Lenalidomide—Fatigue—Metformin—metabolic syndrome X	0.000632	0.00541	CcSEcCtD
Lenalidomide—Constipation—Metformin—metabolic syndrome X	0.000626	0.00536	CcSEcCtD
Lenalidomide—Feeling abnormal—Metformin—metabolic syndrome X	0.000604	0.00517	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Metformin—metabolic syndrome X	0.000599	0.00513	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—metabolic syndrome X	0.000585	0.00512	CbGpPWpGaD
Lenalidomide—Urticaria—Metformin—metabolic syndrome X	0.000582	0.00498	CcSEcCtD
Lenalidomide—Abdominal pain—Metformin—metabolic syndrome X	0.000579	0.00496	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—metabolic syndrome X	0.000544	0.00476	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—GGT1—metabolic syndrome X	0.000532	0.00466	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—metabolic syndrome X	0.000531	0.00464	CbGpPWpGaD
Lenalidomide—ABCB1—liver—metabolic syndrome X	0.000528	0.00489	CbGeAlD
Lenalidomide—Asthenia—Metformin—metabolic syndrome X	0.000526	0.0045	CcSEcCtD
Lenalidomide—Pruritus—Metformin—metabolic syndrome X	0.000518	0.00444	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—IL6—metabolic syndrome X	0.000514	0.0045	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—metabolic syndrome X	0.000502	0.00439	CbGpPWpGaD
Lenalidomide—Diarrhoea—Metformin—metabolic syndrome X	0.000501	0.00429	CcSEcCtD
Lenalidomide—Dizziness—Metformin—metabolic syndrome X	0.000484	0.00415	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—metabolic syndrome X	0.000474	0.00415	CbGpPWpGaD
Lenalidomide—Vomiting—Metformin—metabolic syndrome X	0.000466	0.00399	CcSEcCtD
Lenalidomide—Rash—Metformin—metabolic syndrome X	0.000462	0.00395	CcSEcCtD
Lenalidomide—Dermatitis—Metformin—metabolic syndrome X	0.000461	0.00395	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—LPL—metabolic syndrome X	0.000461	0.00403	CbGpPWpGaD
Lenalidomide—Headache—Metformin—metabolic syndrome X	0.000459	0.00393	CcSEcCtD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—NAMPT—metabolic syndrome X	0.000457	0.004	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—PLA2G4A—metabolic syndrome X	0.00044	0.00385	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CD36—metabolic syndrome X	0.000438	0.00383	CbGpPWpGaD
Lenalidomide—Nausea—Metformin—metabolic syndrome X	0.000435	0.00372	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—PLA2G6—metabolic syndrome X	0.000434	0.00379	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SCARB1—metabolic syndrome X	0.000416	0.00364	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—GCK—metabolic syndrome X	0.000401	0.00351	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—metabolic syndrome X	0.000368	0.00322	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—metabolic syndrome X	0.000363	0.00317	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HDAC3—metabolic syndrome X	0.000359	0.00314	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ABCA1—metabolic syndrome X	0.00035	0.00306	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GGT1—metabolic syndrome X	0.000339	0.00296	CbGpPWpGaD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—APOA1—metabolic syndrome X	0.00033	0.00288	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MTNR1B—metabolic syndrome X	0.000321	0.00281	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—metabolic syndrome X	0.000315	0.00276	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TRIB3—metabolic syndrome X	0.000313	0.00274	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RBP4—metabolic syndrome X	0.000313	0.00274	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—metabolic syndrome X	0.000304	0.00266	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—metabolic syndrome X	0.000293	0.00256	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—APOB—metabolic syndrome X	0.000287	0.00251	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOC3—metabolic syndrome X	0.000277	0.00243	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HTR2C—metabolic syndrome X	0.00025	0.00219	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CYBA—metabolic syndrome X	0.000242	0.00212	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GHRL—metabolic syndrome X	0.000237	0.00207	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—metabolic syndrome X	0.000235	0.00206	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—APOA1—metabolic syndrome X	0.000227	0.00199	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR1—metabolic syndrome X	0.000225	0.00196	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—metabolic syndrome X	0.000205	0.0018	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EPHX2—metabolic syndrome X	0.000197	0.00173	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—INS—metabolic syndrome X	0.000197	0.00172	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CCL2—metabolic syndrome X	0.000193	0.00169	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF2—metabolic syndrome X	0.000184	0.00161	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—LEP—metabolic syndrome X	0.000182	0.00159	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—metabolic syndrome X	0.000181	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—metabolic syndrome X	0.00018	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—metabolic syndrome X	0.000179	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOB—metabolic syndrome X	0.000178	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL5—metabolic syndrome X	0.000174	0.00152	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PLA2G4A—metabolic syndrome X	0.000173	0.00152	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LPL—metabolic syndrome X	0.00017	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—metabolic syndrome X	0.000167	0.00146	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—metabolic syndrome X	0.000161	0.00141	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FABP4—metabolic syndrome X	0.000158	0.00138	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SIRT1—metabolic syndrome X	0.000157	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCL2—metabolic syndrome X	0.000153	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—metabolic syndrome X	0.00015	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSD11B1—metabolic syndrome X	0.00015	0.00131	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AGT—metabolic syndrome X	0.000146	0.00127	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOE—metabolic syndrome X	0.000143	0.00125	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LEP—metabolic syndrome X	0.000143	0.00125	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOA1—metabolic syndrome X	0.000141	0.00123	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HDAC3—metabolic syndrome X	0.00013	0.00114	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IRS1—metabolic syndrome X	0.000127	0.00111	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPA—metabolic syndrome X	0.000127	0.00111	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—G6PC2—metabolic syndrome X	0.000125	0.00109	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G6—metabolic syndrome X	0.000123	0.00108	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA5—metabolic syndrome X	0.000122	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INS—metabolic syndrome X	0.000122	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL2—metabolic syndrome X	0.00012	0.00105	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1—metabolic syndrome X	0.000118	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—TRIB3—metabolic syndrome X	0.000113	0.000992	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SERPINE1—metabolic syndrome X	0.000112	0.000979	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—metabolic syndrome X	0.000111	0.000973	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOS3—metabolic syndrome X	0.000107	0.000935	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—metabolic syndrome X	0.000107	0.000933	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—metabolic syndrome X	0.000106	0.000931	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—metabolic syndrome X	0.000102	0.000895	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LIPC—metabolic syndrome X	0.000101	0.000884	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOC3—metabolic syndrome X	0.0001	0.000879	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—G6PC2—metabolic syndrome X	9.87e-05	0.000863	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FMO3—metabolic syndrome X	9.86e-05	0.000863	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CETP—metabolic syndrome X	9.75e-05	0.000853	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—metabolic syndrome X	9.34e-05	0.000817	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SREBF1—metabolic syndrome X	9.06e-05	0.000793	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—metabolic syndrome X	9.01e-05	0.000789	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HMGCR—metabolic syndrome X	8.82e-05	0.000771	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—metabolic syndrome X	8.81e-05	0.000771	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EPHX2—metabolic syndrome X	8.79e-05	0.000769	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MLXIPL—metabolic syndrome X	8.79e-05	0.000769	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—metabolic syndrome X	8.59e-05	0.000751	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—GCKR—metabolic syndrome X	8.57e-05	0.00075	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—metabolic syndrome X	8.42e-05	0.000736	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—G6PC2—metabolic syndrome X	8.26e-05	0.000723	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—metabolic syndrome X	8.22e-05	0.00072	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—metabolic syndrome X	7.86e-05	0.000687	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—metabolic syndrome X	7.61e-05	0.000666	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—metabolic syndrome X	7.25e-05	0.000634	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—G6PD—metabolic syndrome X	7.09e-05	0.00062	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—metabolic syndrome X	7.07e-05	0.000619	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—metabolic syndrome X	7.07e-05	0.000618	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FABP4—metabolic syndrome X	7.03e-05	0.000615	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FMO3—metabolic syndrome X	6.99e-05	0.000612	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HDAC3—metabolic syndrome X	6.92e-05	0.000605	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—GCK—metabolic syndrome X	6.81e-05	0.000596	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—metabolic syndrome X	6.79e-05	0.000594	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GCKR—metabolic syndrome X	6.76e-05	0.000592	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HSD11B1—metabolic syndrome X	6.66e-05	0.000583	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CETP—metabolic syndrome X	6.57e-05	0.000575	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	6.46e-05	0.000565	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	6.28e-05	0.00055	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EPHX2—metabolic syndrome X	6.23e-05	0.000545	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MLXIPL—metabolic syndrome X	6.23e-05	0.000545	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	6.17e-05	0.000539	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—metabolic syndrome X	6.13e-05	0.000536	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RBP4—metabolic syndrome X	6.03e-05	0.000527	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TRIB3—metabolic syndrome X	6.03e-05	0.000527	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—metabolic syndrome X	6.01e-05	0.000526	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—G6PD—metabolic syndrome X	5.94e-05	0.000519	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	5.86e-05	0.000513	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—G6PC2—metabolic syndrome X	5.86e-05	0.000513	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HDAC3—metabolic syndrome X	5.8e-05	0.000507	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—metabolic syndrome X	5.73e-05	0.000501	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCKR—metabolic syndrome X	5.66e-05	0.000496	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LPA—metabolic syndrome X	5.66e-05	0.000496	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G6—metabolic syndrome X	5.49e-05	0.00048	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	5.45e-05	0.000477	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA5—metabolic syndrome X	5.43e-05	0.000475	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NAMPT—metabolic syndrome X	5.41e-05	0.000473	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GCK—metabolic syndrome X	5.37e-05	0.00047	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOC3—metabolic syndrome X	5.34e-05	0.000467	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—metabolic syndrome X	5.33e-05	0.000466	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A4—metabolic syndrome X	5.3e-05	0.000463	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	5.28e-05	0.000461	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	5.17e-05	0.000452	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	5.11e-05	0.000447	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TRIB3—metabolic syndrome X	5.05e-05	0.000442	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FABP4—metabolic syndrome X	4.98e-05	0.000436	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HMGA1—metabolic syndrome X	4.91e-05	0.00043	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—metabolic syndrome X	4.91e-05	0.00043	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HSD11B1—metabolic syndrome X	4.72e-05	0.000413	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GOT2—metabolic syndrome X	4.69e-05	0.00041	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CYBA—metabolic syndrome X	4.67e-05	0.000408	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAMPT—metabolic syndrome X	4.53e-05	0.000396	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	4.5e-05	0.000394	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LIPC—metabolic syndrome X	4.5e-05	0.000394	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCK—metabolic syndrome X	4.5e-05	0.000394	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOC3—metabolic syndrome X	4.47e-05	0.000391	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—APOB—metabolic syndrome X	4.35e-05	0.000381	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—metabolic syndrome X	4.35e-05	0.00038	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CETP—metabolic syndrome X	4.34e-05	0.00038	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—metabolic syndrome X	4.26e-05	0.000373	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—G6PD—metabolic syndrome X	4.21e-05	0.000368	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC2A4—metabolic syndrome X	4.18e-05	0.000366	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SCARB1—metabolic syndrome X	4.16e-05	0.000364	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HDAC3—metabolic syndrome X	4.11e-05	0.000359	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—metabolic syndrome X	4.06e-05	0.000355	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	4.05e-05	0.000354	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GOT1—metabolic syndrome X	4.05e-05	0.000354	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SREBF1—metabolic syndrome X	4.04e-05	0.000353	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LPA—metabolic syndrome X	4.02e-05	0.000351	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCKR—metabolic syndrome X	4.02e-05	0.000351	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMGCR—metabolic syndrome X	3.93e-05	0.000343	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GOT2—metabolic syndrome X	3.93e-05	0.000343	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G6—metabolic syndrome X	3.89e-05	0.00034	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA5—metabolic syndrome X	3.85e-05	0.000337	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—metabolic syndrome X	3.67e-05	0.000321	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TRIB3—metabolic syndrome X	3.58e-05	0.000313	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCA1—metabolic syndrome X	3.5e-05	0.000306	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A4—metabolic syndrome X	3.5e-05	0.000306	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—APOA1—metabolic syndrome X	3.44e-05	0.000301	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOB—metabolic syndrome X	3.43e-05	0.0003	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GGT1—metabolic syndrome X	3.39e-05	0.000297	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GOT1—metabolic syndrome X	3.39e-05	0.000297	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LPL—metabolic syndrome X	3.28e-05	0.000287	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAMPT—metabolic syndrome X	3.21e-05	0.000281	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LIPC—metabolic syndrome X	3.19e-05	0.000279	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCK—metabolic syndrome X	3.19e-05	0.000279	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOC3—metabolic syndrome X	3.17e-05	0.000277	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CETP—metabolic syndrome X	3.08e-05	0.000269	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—metabolic syndrome X	3.02e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SCARB1—metabolic syndrome X	2.95e-05	0.000258	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOB—metabolic syndrome X	2.88e-05	0.000252	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SREBF1—metabolic syndrome X	2.86e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G4A—metabolic syndrome X	2.8e-05	0.000245	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMGCR—metabolic syndrome X	2.78e-05	0.000243	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GOT2—metabolic syndrome X	2.78e-05	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—metabolic syndrome X	2.75e-05	0.00024	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LPL—metabolic syndrome X	2.75e-05	0.00024	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—metabolic syndrome X	2.73e-05	0.000239	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOA1—metabolic syndrome X	2.72e-05	0.000238	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CD36—metabolic syndrome X	2.61e-05	0.000228	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCA1—metabolic syndrome X	2.48e-05	0.000217	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A4—metabolic syndrome X	2.48e-05	0.000217	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IRS1—metabolic syndrome X	2.45e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARA—metabolic syndrome X	2.43e-05	0.000212	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GOT1—metabolic syndrome X	2.4e-05	0.00021	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GGT1—metabolic syndrome X	2.4e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AGT—metabolic syndrome X	2.35e-05	0.000206	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—INS—metabolic syndrome X	2.35e-05	0.000205	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—metabolic syndrome X	2.3e-05	0.000201	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA1—metabolic syndrome X	2.28e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SERPINE1—metabolic syndrome X	2.16e-05	0.000189	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—metabolic syndrome X	2.06e-05	0.00018	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOB—metabolic syndrome X	2.04e-05	0.000178	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—metabolic syndrome X	2e-05	0.000175	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G4A—metabolic syndrome X	1.98e-05	0.000173	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—INS—metabolic syndrome X	1.97e-05	0.000172	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LPL—metabolic syndrome X	1.95e-05	0.00017	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CD36—metabolic syndrome X	1.85e-05	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—metabolic syndrome X	1.8e-05	0.000158	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—metabolic syndrome X	1.72e-05	0.000151	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARA—metabolic syndrome X	1.72e-05	0.00015	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AGT—metabolic syndrome X	1.67e-05	0.000146	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—metabolic syndrome X	1.63e-05	0.000143	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA1—metabolic syndrome X	1.61e-05	0.000141	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—metabolic syndrome X	1.42e-05	0.000124	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—INS—metabolic syndrome X	1.39e-05	0.000122	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—metabolic syndrome X	1.36e-05	0.000119	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—metabolic syndrome X	1.28e-05	0.000112	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—metabolic syndrome X	1.22e-05	0.000107	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—metabolic syndrome X	1.12e-05	9.78e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—metabolic syndrome X	1.03e-05	8.98e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—metabolic syndrome X	9.47e-06	8.28e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—metabolic syndrome X	7.93e-06	6.93e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—metabolic syndrome X	5.62e-06	4.92e-05	CbGpPWpGaD
